ANIP Stock Outlook: Cortrophin Growth vs. Retina Reset

ANI Pharmaceuticals' growth pivots to Cortrophin Gel as retina headwinds weigh on 2025, with 2026 recovery hopes hinging on specialty momentum and portfolio res

Go to News Site